薈萃國際控股(08041.HK):B系列優先股轉換價調整為0.30港元
格隆匯 8 月 5日丨薈萃國際控股(08041.HK)公告,根據可換股優先股條款,由於股份合併,發行在外的可換股優先股轉換價由每股股份0.12港元調整為每股股份1.20港元。所述調整將於2020年8月7日(即股份合併的生效日期)生效。根據公司核數師報告,所述調整符合可換股優先股條款。
根據B系列可換股優先股條款,由於股份合併,發行在外的B系列可換股優先股轉換價由每股股份0.030港元調整為每股股份0.30港元。所述調整將於2020年8月7日(即股份合併的生效日期)生效。根據公司核數師報告,所述調整符合B系列可換股優先股條款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.